ReviewUnited European gastroenterology journal2019
Clinical management of autoimmune hepatitis.
Review in United European gastroenterology journal, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 86 citations in OpenAlex.
- The detrimental effect of autoimmune hepatitis in pregnancy: a systematic review and meta-analysis.Annals of medicine and surgery (2012) · 2025Article
- Present and Future Perspectives in the Treatment of Liver Fibrosis.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Efficacy and Safety of Mycophenolate Mofetil Compared to Azathioprine in Autoimmune Hepatitis: A Meta-Analysis.Gastroenterology research · 2025Article
- Identifying the genetic link between type 1 diabetes and autoimmune liver diseases.Clinical and experimental hepatology · 2025Article
- Pharmacotherapy of Liver Fibrosis and Hepatitis: Recent Advances.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Increased Risk of Non-Hodgkin Lymphoma in Autoimmune Hepatitis: A Large Retrospective Cohort Study.Journal of clinical medicine · 2024Article
- Analysis of Azathioprine Metabolites in Autoimmune Hepatitis Patient Blood-Method Development and Validation.International journal of molecular sciences · 2024Article
- Co-occurrence of anti-phospholipid syndrome and posterior reversible encephalopathy syndrome in a patient with Autoimmune hepatitis: A case report.Radiology case reports · 2024Article
- A Rare Case of Bullous Morphea Associated with Autoimmune Hepatitis.Journal of clinical medicine · 2024Article
- Role of Sirolimus and Rituximab in the Treatment of Autoimmune Hepatitis.ACG case reports journal · 2024Article
- Hepatic and Extrahepatic Characteristics of Autoimmune Hepatitis: A 23-year Hospital-Based Cohort Study.Digestive diseases and sciences · 2024Article
- Article
- Enhancing Liver Delivery of Gold Nanoclusters via Human Serum Albumin Encapsulation for Autoimmune Hepatitis Alleviation.Pharmaceutics · 2024Article
- Rare co-occurrence of probable pernicious anemia and autoimmune hepatitis in a 55-year-old male patient: A case report.SAGE open medical case reports · 2024Article
- Autoimmune Hepatitis: An Unusual Presentation.Journal of community hospital internal medicine perspectives · 2024Article
- Metabolic Reprogramming of CD4International journal of nanomedicine · 2024Article
- Liver-Targeting Nanoplatforms for the Induction of Immune Tolerance.Nanomaterials (Basel, Switzerland) · 2023Review
- CD4+ T-cell subsets in autoimmune hepatitis: A review.Hepatology communications · 2023Review
- Autoimmune hepatitis presenting with concomitant chronic pancreatitis.Radiology case reports · 2023Article
- Clinical characteristics and outcomes of COVID-19 in patients with autoimmune hepatitis: A population-based matched cohort study.World journal of hepatology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autoimmune hepatitis is a rare and chronic liver disease that is characterised by increased serum transaminases and immunoglobulin G, inflammatory liver histology and presence of circulating autoantibodies. An autoimmune hepatitis diagnosis justifies life-long treatment in most patients in order to prevent development of cirrhosis and end-stage liver disease. The cornerstone of treatment is steroid induction therapy followed by maintenance therapy with azathioprine, which is effective in most cases. For patients who do not respond to standard treatment, second-line treatment with other immunosuppressants can be effective. Treatment should be aimed at biochemical remission of the disease, which is defined as normalization of transaminases and immunoglobulin G. Patients should be monitored intensively during the first months of treatment in order to monitor side-effects, assess symptoms and individualise treatment. Specialist consultation should be sought in difficult-to-treat patients. Future studies and networking initiatives should result in optimization of current treatment strategies in autoimmune hepatitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.